The DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) membrane (M) protein inhibits type I and III interferon production by targeting RIG-I/MDA-5 signaling
Open accessPublished version of a preprint
Abstract
Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has quickly spread worldwide and has affected more than 10 million individuals. A typical feature of COVID-19 is the suppression of type I and III interferon (IFN)-mediated antiviral immunity. However, the molecular mechanism by which SARS-CoV-2 evades antiviral immunity remains elusive. Here, we reported that the SARS-CoV-2 membrane (M) protein inhibits the production of type I and III IFNs induced by the cytosolic dsRNA-sensing pathway mediated by RIG-I/MDA-5-MAVS signaling. In addition, the SARS-CoV-2 M protein suppresses type I and III IFN induction stimulated by SeV infection or poly (I:C) transfection. Mechanistically, the SARS-CoV-2 M protein interacts with RIG-I, MAVS, and TBK1, thus preventing the formation of the multiprotein complex containing RIG-I, MAVS, TRAF3, and TBK1 and subsequently impeding the phosphorylation, nuclear translocation, and activation of IRF3. Consequently, ectopic expression of the SARS-CoV-2 M protein facilitates the replication of vesicular stomatitis virus. Taken together, these results indicate that the SARS-CoV-2 M protein antagonizes type I and III IFN production by targeting RIG-I/MDA-5 signaling, which subsequently attenuates antiviral immunity and enhances viral replication. This study provides insight into the interpretation of SARS-CoV-2-induced antiviral immune suppression and illuminates the pathogenic mechanism of COVID-19.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Figures







Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“As is typical for many viruses, IFNs inhibit viral replication and are elevated during COVID-19, which helps drive Th1 and Th17 responses. 149,150”
From COVID-19, Myocarditis and Pericarditis (2023) · cites this paper as [149]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A novel coronavirus from patients with pneumonia in China, 2019
Zhu, N., Zhang, D., Wang, W., Li, X., Yang, B., Song, J., Zhao, X., Huang, B., Shi, W., Lu, R., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2001017 · Cited by 28,244
A pneumonia outbreak associated with a new coronavirus of probable bat origin
Zhou, P., Yang, X.-L., Wang, X.-G., Hu, B., Zhang, L., Zhang, W., Si, H.-R., Zhu, Y., Li, B., Huang, C.-L., et al. (2020) · Nature · doi:10.1038/s41586-020-2012-7 · Cited by 21,969
A new coronavirus associated with human respiratory disease in China
Wu, F., Zhao, S., Yu, B., Chen, Y.-M., Wang, W., Song, Z.-G., Hu, Y., Tao, Z.-W., Tian, J.-H., Pei, Y.-Y., et al. (2020) · Nature · doi:10.1038/s41586-020-2008-3 · Cited by 11,688
Origin and evolution of pathogenic coronaviruses
Cui, J., Li, F., & Shi, Z. (2018) · Nature Reviews Microbiology · doi:10.1038/s41579-018-0118-9 · Cited by 5,729
Cyclic GMP-AMP Synthase Is a Cytosolic DNA Sensor That Activates the Type I Interferon Pathway
Sun, L., Wu, J., Du, F., Chen, X., & Chen, Z. J. (2013) · Science · doi:10.1126/science.1232458 · Cited by 4,996
Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19
Blanco-Melo, D., Nilsson-Payant, B. E., Liu, W.-C., Uhl, S., Hoagland, D., Møller, R., Jordan, T. X., Oishi, K., Panis, M., Sachs, D., et al. (2020) · Cell · doi:10.1016/j.cell.2020.04.026 · Cited by 4,222
Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients
Hadjadj, J., Yatim, N., Barnabei, L., Corneau, A., Boussier, J., Smith, N., Péré, H., Charbit, B., Bondet, V., Chenevier-Gobeaux, C., et al. (2020) · Science · doi:10.1126/science.abc6027 · Cited by 2,984
Ziegler, C. G. K., Allon, S. J., Nyquist, S. K., Mbano, I. M., Miao, V. N., Tzouanas, C. N., Cao, Y., Yousif, A. S., Bals, J., Hauser, B. M., et al. (2020) · Cell · doi:10.1016/j.cell.2020.04.035 · Cited by 2,284
The Architecture of SARS-CoV-2 Transcriptome
Kim, D., Lee, J.-Y., Yang, J.-S., Kim, J. W., Kim, V. N., & Chang, H. (2020) · Cell · doi:10.1016/j.cell.2020.04.011 · Cited by 2,123
Longitudinal analyses reveal immunological misfiring in severe COVID-19
Lucas, C., Wong, P., Klein, J., Castro, T. B. R., Silva, J., Sundaram, M., Ellingson, M. K., Mao, T., Oh, J. E., Israelow, B., et al. (2020) · Nature · doi:10.1038/s41586-020-2588-y · Cited by 2,074
Cited by
Sorted by citations
Items 201–300 of 302
Gazzinelli-Guimarães, P. H., Sanku, G., Sette, A., Weiskopf, D., Schaughency, P., Lack, J., & Nutman, T. B. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.883159 · Cited by 7
Cellular Sensors and Viral Countermeasures: A Molecular Arms Race between Host and SARS-CoV-2
Sun, H., Chan, J. F., & Yuan, S. (2023) · Viruses · doi:10.3390/v15020352 · Cited by 8
Baldassarro, V. A., Alastra, G., Cescatti, M., Quadalti, C., Lorenzini, L., Giardino, L., & Calzà, L. (2024) · Cell and Tissue Research · doi:10.1007/s00441-024-03900-y · Cited by 6
Regulating the microenvironment with nanomaterials: Potential strategies to ameliorate COVID-19
Liu, Z., Han, Z., Jin, X., An, J., Kim, J., Chen, W., Kim, J. S., Zheng, J., & Deng, J. (2023) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2023.02.010 · Cited by 6
Interferon-lambda: New functions on intestinal symptoms in COVID-19
Pan, Y., Wang, L.-C., Yang, F., & Yu, M. (2023) · World Journal of Gastroenterology · doi:10.3748/wjg.v29.i13.1942 · Cited by 7
Immune modulation: the key to combat SARS-CoV-2 induced myocardial injury
Li, Z., Qin, L., Xu, X., Chen, R., Zhang, G., Wang, B., Li, B., & Chu, X. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1561946 · Cited by 6
How SARS-CoV-2 dodges immune surveillance and facilitates infection: an analytical review
Wang, Q., Wu, X., Mao, Q., Gao, F., Liu, M., Song, Z., Bian, L., & Liang, Z. (2022) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2022.2078307 · Cited by 5
Development of FRET and Stress Granule Dual-Based System to Screen for Viral 3C Protease Inhibitors
Zhang, J., Jiang, Y., Wu, C., Zhou, D., Jufang, G., Zhao, T., & Jin, Z. (2023) · Molecules · doi:10.3390/molecules28073020 · Cited by 6
Self-citationZheng, Y., Yang, H., Zhang, X., & Gao, C. (2023) · Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms · doi:10.1016/j.bbagrm.2023.194984 · Cited by 6
Self-citationGao, H., Wang, S., Duan, H., Wang, Y., & Zhu, H. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1290578 · Cited by 6
Pinski, A. N., Steffen, T. L., Zulu, M. Z., George, S. L., Dickson, A., Tifrea, D., Maroney, K. J., Tedeschi, N., Zhang, Y., Scheuermann, R. H., et al. (2021) · Journal of Leukocyte Biology · doi:10.1002/jlb.4cova0121-084rr · Cited by 6
Immune responses to human respiratory coronaviruses infection in mouse models
Zhuang, Z., Liu, D., Sun, J., Li, F., & Zhao, J. (2021) · Current Opinion in Virology · doi:10.1016/j.coviro.2021.11.015 · Cited by 6
Promising Immunotherapies against COVID‐19
Guo, H., Zhou, L., Ma, Z., Tian, Z., & Zhou, F. (2021) · Advanced Therapeutics · doi:10.1002/adtp.202100044 · Cited by 6
The viral early protein 4 of human papillomavirus type 16 suppresses innate antiviral immunity
Chen, H., Zhang, J., Li, J., Li, C., Li, Y., Zhang, Q., Kong, B., & Wang, P. (2025) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2025.144542 · Cited by 5
Self-citationLu, Y., Qi, Y., Yinliang, Q., Zhu, R., Sarapultsev, A., Luo, S., Cui, J., & Hu, D. (2025) · Cell & Bioscience · doi:10.1186/s13578-025-01512-9 · Cited by 5
Vitamin D regulates COVID-19 associated severity by suppressing the NLRP3 inflammasome pathway
Khalil, B. A., Sharif‐Askari, N. S., Hafezi, S., Sharif‐Askari, F. S., Anouti, F. A., Hamid, Q. A., & Halwani, R. (2024) · PLoS ONE · doi:10.1371/journal.pone.0302818 · Cited by 6
Zebrafish FKBP5 facilitates apoptosis and SVCV propagation by suppressing NF-κB signaling pathway
Yin, Z., Zhang, H., Zhao, K., Liu, Y., Guo, R., Xu, P., Zhao, G., Hu, C., Hu, C., & Xu, X. (2024) · Fish & Shellfish Immunology · doi:10.1016/j.fsi.2024.110021 · Cited by 5
Baek, S.-H., & Park, J.-E. (2025) · Animals · doi:10.3390/ani15020149 · Cited by 5
Huang, R. Y., & Herr, D. R. (2021) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2021.05.073 · Cited by 5
Mahanta, S., Naiya, T., Biswas, K., Changkakoti, L., Mohanta, Y. K., Tanti, B., Mishra, A. K., Mohanta, T. K., & Sharma, N. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.805344 · Cited by 5
Multifaceted role of SARS-CoV-2 structural proteins in lung injury
Zheng, G., Qiu, G., Qian, H., Shu, Q., & Xu, J. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1332440 · Cited by 6
Profiling of SARS-CoV-2 Subgenomic RNAs in Clinical SpecimensPreprint
Chen, Z., Ng, R. W. Y., Lui, G. C.-Y., Ling, L., Chow, C., Yeung, A. C. M., Boon, S. S., Wang, M. H., Chan, K. C. C., Chan, R. W. Y., et al. (2021) · SSRN Electronic Journal · doi:10.2139/ssrn.3987999 · Cited by 5
Schoen, A., Hölzer, M., Müller, M. A., Wallerang, K. B., Drosten, C., Marz, M., Lamp, B., & Weber, F. (2023) · Journal of Virology · doi:10.1128/jvi.00205-23 · Cited by 4
Zhang, Y., Zhang, X., Zheng, H., & Liu, L. (2022) · Biomolecules · doi:10.3390/biom12111680 · Cited by 5
Abavisani, M., Rahimian, K., Kodori, M., Khayami, R., Sisakht, M. M., Mahmanzar, M., & Meshkat, Z. (2022) · PubMed Central · doi:10.22038/ijbms.2022.66649.14620 · Cited by 4
Obeid, D. A., Alnemari, R., Al-Qahtani, A. A., Alsanea, M. S., Alahideb, B. M., Alsuwairi, F. A., Abdulkarim, M., & Alhamlan, F. S. (2022) · BMJ Open · doi:10.1136/bmjopen-2022-060775 · Cited by 4
Carp, T.-N., Metoudi, M., & Ojha, V. (2024) · Preprints.org · doi:10.20944/preprints202212.0155.v6 · Cited by 4
Unraveled role of TLR7-mediated interferon signaling activation in COVID-19
Xue, J., Wang, X.-Y., Wang, P., Qiao, B., Gao, P., Ren, B., & Yan, S. (2025) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2025.1658249 · Cited by 6
Self-citationJiang, S., Yuan, J., Li, Q., Song, Z., Cao, L., Song, Z., & Zhang, X. (2026) · Frontiers in Microbiology · doi:10.3389/fmicb.2026.1762041 · Cited by 3
Ghoreshi, Z., Behboudi, E., Askarpour, H., Nejad, F. R., & Arefinia, N. (2024) · American Journal of Tropical Medicine and Hygiene · doi:10.4269/ajtmh.24-0004 · Cited by 3
Anti-interferon armamentarium of human coronaviruses
Khatun, O., Kaur, S., & Tripathi, S. (2025) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-025-05605-z · Cited by 3
Torices, S., Moreno, T., Osborne, O., Ramaswamy, S., Naranjo, O., Téglás, T., Park, M., Sun, E., & Toborek, M. J. (2025) · Brain · doi:10.1093/brain/awaf262 · Cited by 8
Can the immune system be targeted to treat COVID-19?
Abdelhafeez, S., & Doherty, D. G. (2021) · European Respiratory Society eBooks · doi:10.1183/2312508x.10024120 · Cited by 3
Wells, E. W., & Parker, M. T. (2023) · Health Security · doi:10.1089/hs.2023.0008 · Cited by 3
Wang, Z., Zhou, M., Fu, Z., & Zhao, L. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.693579 · Cited by 3
Wang, Y., Wu, F., Fan, D., Lin, A., Xiang, L., Chen, Y., & Shao, J.-Z. (2025) · Journal of Virology · doi:10.1128/jvi.01387-25 · Cited by 2
Yang, H., Peng, D., Martínez‐Sobrido, L., & Ye, C. (2026) · Microbiology Spectrum · doi:10.1128/spectrum.02915-25 · Cited by 2
Kunapaisal, T., Guo, S., Gomez, C., Théard, M. A., Lynch, J. B., Lele, A. V., King, M. A., Buckley, R., & Vavilala, M. S. (2023) · Cureus · doi:10.7759/cureus.36258 · Cited by 2
Modeling of SARS-CoV-2 Virus Proteins: Implications on Its Proteome
Sarkar, M., & Saha, S. (2023) · Methods in molecular biology · doi:10.1007/978-1-0716-2974-1_15 · Cited by 2
Siddique, A. I., Sarmah, N., Bali, N. K., Nausch, N., & Borkakoty, B. (2024) · Journal of Medical Virology · doi:10.1002/jmv.70074 · Cited by 2
A20 as a Potential Therapeutic Target for COVID‐19
Wu, Y., Li, H., Li, R., Li, J., Zhao, Q., & Shao, B. (2025) · Immunity Inflammation and Disease · doi:10.1002/iid3.70127 · Cited by 2
Impact of SARS-CoV-2 Variant NSP6 on Pathogenicity: Genetic Analysis and Cell Biology
Gao, Y., Ni, P., Hua, Y., Chen, S., & Zhang, R. (2025) · Current Issues in Molecular Biology · doi:10.3390/cimb47050361 · Cited by 2
Design and Immunogenicity of SARS-CoV-2 DNA Vaccine Encoding RBD-PVXCP Fusion Protein
Dormeshkin, D., Katsin, M., Stegantseva, M. V., Golenchenko, S., Shapira, M. A., Dubovik, S., Lutskovich, D. V., Kavaleuski, A., & Meleshko, A. (2023) · Vaccines · doi:10.3390/vaccines11061014 · Cited by 3
Immunoediting in SARS-CoV-2: Mutual relationship between the virus and the host
Kheshtchin, N., Bakhshi, P., Arab, S., & Nourizadeh, M. (2022) · International Immunopharmacology · doi:10.1016/j.intimp.2022.108531 · Cited by 2
Sun, M., Hao, F., Li, W., Cheng, Z., Zhang, W., Yang, L., Mao, L., & Liu, M. (2022) · Viruses · doi:10.3390/v14051025 · Cited by 2
Low-Dose Interferon I and III-Based Nasal Sprays: A Good-Looking COVID-19 Vaccine Candidate?Preprint
Carp, T.-N., & Metoudi, M. (2022) · Preprints.org · doi:10.20944/preprints202212.0155.v2 · Cited by 1
Carp, T.-N., Metoudi, M., Brown, B., & Ojha, V. (2023) · Preprints.org · doi:10.20944/preprints202212.0155.v4 · Cited by 2
Torices, S., Moreno, T., Ramaswamy, S., Naranjo, O., Téglás, T., Osborne, O., Park, M., Sun, E., & Toborek, M. J. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.06.07.598027 · Cited by 2
Structural proteins of SARS-CoV-2
Duvanova, O. V., Чемисова, О. С., & Носков, А. К. (2022) · Medical Herald of the South of Russia · doi:10.21886/2219-8075-2022-13-4-45-52 · Cited by 1
Francis, N. A., Monk, P., Nuttall, J., Oliver, T., Simpson, C., Brookes, J. L., Tear, V. J., Thompson, A. G., Batten, T. N., Mankowski, M., et al. (2023) · BJGP Open · doi:10.3399/bjgpo.2023.0089 · Cited by 1
Zhang, J., Xia, Y., Li, X., He, R.-X., & Xie, X. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1302504 · Cited by 1
Self-citationHurst, J. R., Naghibosadat, M., Budowski, P., Li, J., Samaan, P., Budiman, F., Kurtesi, A., Qi, F., Menon, H., Krishnan, R. G., et al. (2024) · PLoS ONE · doi:10.1371/journal.pone.0314061 · Cited by 1
Low serum S100A6 levels are associated RP-ILD risk in anti-MDA5-positive dermatomyositis
Yan, W., Wu, Q., Shi, Y., You, H., Jia, J., Meng, D., Ma, L., Zhang, X., Yu, X., Tan, W., et al. (2024) · Clinical Rheumatology · doi:10.1007/s10067-024-07265-z · Cited by 1
Li, Y., He, J., Liu, W., Qi, R., Li, J., & Zhu, F. (2025) · Expert Review of Vaccines · doi:10.1080/14760584.2025.2550984 · Cited by 1
Chávez-Tinoco, M., Solís-Cruz, B., López-Mena, E. R., García-Salazar, K. S., Hernández‐Patlan, D., & Mejía-Méndez, J. L. (2025) · Journal of Nanotheranostics · doi:10.3390/jnt6040030 · Cited by 1
LncRNAs in inflammasome regulation: Orchestrating cancer signaling and chemoresistance
Mukhlif, M. Y., Mahmood, S. H., Khalaf, A. A., Sanghvi, G. V., Ballal, S., Singh, A., Sabarivani, A., Mishra, S. S., Mustafa, Y. F., & Yasin, H. A. (2025) · Seminars in Oncology · doi:10.1016/j.seminoncol.2025.152455 · Cited by 1
Beyond assembly: functions of the coronavirus M protein
Kariuki, C. K., Doijen, J., Mann, M. K., Xie, J., Loock, M. V., & Damme, E. V. (2026) · Virology Journal · doi:10.1186/s12985-026-03154-w · Cited by 1
Zhang, T., Peng, X., Qin, J., Zhu, B., Zhang, S., Deng, S., Song, Z., Han, Y., Zheng, H., Chen, J., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-72025-3 · Cited by 1
Self-citationGenetics and Biological Characteristics of SARS-CoV-2
Norouzi, M., Miles, M. A., & Norouzi, S. (2022) · Springer eBooks · doi:10.1007/978-3-031-08045-6_4 · Cited by 2
Exploring COVID-19 causal genes through disease-specific Cis-eQTLs
Zhang, S., Wang, P., Shi, L., Wang, C., Zhu, Z., Qi, C., Xie, Y., Yuan, S., Cheng, L., Yin, X., et al. (2024) · Virus Research · doi:10.1016/j.virusres.2024.199341 · Cited by 1
Self-citationBose, M., & Munshi, C. (2024) · Global Translational Medicine · doi:10.36922/gtm.2228
Inflammatory response to SARS-CoV 2 and other respiratory viruses
Garcés, A. E. V., Cáceres, E. L., Olivella-Gómez, J., Martín‐Loeches, I., & Reyes, L. F. (2024) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2024.2400548 · Cited by 1
SARS-CoV-2 nucleocapsid protein: Importance in viral infection
Haq, H. M. S. U., Kombe, A. J. K., Zahid, A., Babar, M., Zeng, W., He, H., & Jin, T. (2022) · JUSTC · doi:10.52396/justc-2022-0020 · Cited by 1
Zambalde, É. P., Pavan, I. C. B., Mancini, M. C. S., Severino, M. B., Scudero, O. B., Morelli, A. P., Amorim, M. R., Bispo-dos-Santos, K., Góis, M. M., de Toledo-Teixeira, D. A., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.12.06.471464 · Cited by 1
Low-Dose Interferon I and Iii-Based Nasal Sprays: A Good-Looking Covid-19 Vaccine Candidate?Preprint
Carp, T.-N., & Metoudi, M. (2022) · Preprints.org · doi:10.20944/preprints202212.0155.v1
Low-Dose Interferon I and III-Based Nasal Sprays: A Good-Looking COVID-19 Vaccine Candidate?Preprint
Carp, T.-N., Metoudi, M., Brown, B., & Ojha, V. (2023) · Preprints.org · doi:10.20944/preprints202212.0155.v3
Reply to Dorgham et al., “Considering Personalized Interferon Beta Therapy for COVID-19”
Davoudi-Monfared, E., & Khalili, H. (2021) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00083-21
Sánchez, B. G., Gasalla-Herraiz, J., Sánchez‐Chapado, M., Bort, A., & Díaz‐Laviada, I. (2021) · Research Square · doi:10.21203/rs.3.rs-769766/v1
Charakterystyka betacoronavirusów oraz wariantów SARS-CoV-2
Kwiatek, A., & Dudek, I. (2021) · Kosmos · doi:10.36921/kos.2021_2832
Elkazzaz, M., Hayadara, T., Abo-Amer, Y. E.-E., Shamkh, I. M., & Magd, M. F. A. E. (2022) · doi:10.31219/osf.io/a6r3g
Elkazzaz, M., Hayadara, T., Abo-Amer, Y. E.-E., Shamkh, I. M., Magd, M. F. A. E., Sarohan, A. R., & Alshuwaier, G. O. (2022) · doi:10.31219/osf.io/p7gfe
Multi-receptor mechanism and retinoid signaling disorder in the pathogenesis of COVID-19Preprint
Elkazzaz, M., Haydara, T., Abo-Amer, Y. E.-E., Shamkh, I. M., Magd, M. F. A. E., & Ahmed, A. K. K. (2022) · doi:10.14293/s2199-1006.1.sor-.ppxlyqw.v1
Crystal structure of the membrane (M) protein from a SARS-COV-2-related coronavirusPreprint
Wang, X., Yang, Y., Sun, Z., & Zhou, X. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.06.28.497981
Genomic, proteomic and metabolomic profiling of severe acute respiratory syndrome-Coronavirus-2
Mathew, B. J., Gupta, S., Nema, R. K., Vyas, A. K., Khare, P. S., Biswas, D., & Singh, A. K. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-91172-6.00019-4
Seviiri, M. (2022) · Queensland University of Technology · doi:10.5204/thesis.eprints.236969
Checa., I. D. M. M. Y. T. F. D. M. Y. O. I. C. D. T. A. E. I. (. U. D. P. O. R., & Garmendia, J. V. (2022) · Gaceta Médica de Caracas · doi:10.47307/gmc.2022.130.4.16
Innate immune responses in COVID-19
Jacotot, E. D., Talamini, L., Bonam, S. R., Vieira, A. T., Frémeaux‐Bacchi, V., Radic, M. Z., Dragon‐Durey, M., Lozano, J. M., Saia, R. S., & Muller, S. (2023) · Elsevier eBooks · doi:10.1016/b978-0-443-18566-3.00041-4
SARS-CoV-2: Structure, Pathogenesis, and Diagnosis
Goverdhan, A. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-87539-4.00002-6
Interference of SARS-CoV-2 on type Ⅰ IFN-mediated antiviral response
Wei, L. (2023) · International Conference on Modern Medicine and Global Health (ICMMGH) · doi:10.1117/12.2692178
Pharmacology of Glycyrrhiza glabra (Mulhatti): The grandfather of herbs
Srivastav, A. K., & Singh, V. K. (2022) · Journal Of Biotechnology And Crop Science · doi:10.5958/2582-5089.2022.00005.6
Chandra, K., Das, A. K., Banday, S., Dhyani, N., Upadhyay, B., Dang, A., Joshi, S., & Dudeja, M. (2022) · Indian Journal of Pathology and Microbiology · doi:10.4103/ijpm.ijpm_178_22
Research Progress on the Mechanism of COVID-19 Gastrointestinal Symptoms
白, 延. (2024) · Advances in Clinical Medicine · doi:10.12677/acm.2024.1461844
Biotecnología aplicada al diagnóstico y tratamiento de la COVID
Prync, A. E. S., Carlucci, A. M., Restovich, D. C., Fabro, J. P., Ficco, M., Belen, B., Ingolotti, S. P., Negro, A., Bustos, F., & Stabile, G. B. (2022) · Revista Bioquímica y Patología Clínica · doi:10.62073/bypc.v86i2.192
Osborn, R. M., Anderson, C., Leach, J. R., Chu, C., Dewhurst, S., Mariani, T. J., & Thakar, J. (2024) · Clinical & Experimental Immunology · doi:10.1093/cei/uxae118 · Cited by 1
SARS-CoV-2 encoded ORF3a interacts with YY1 to promote latent HCMV reactivation
Xia, S., Huo, X., Liu, N., Liu, X., Wang, T., Guo, M., Zeng, C., Wan, P., & Chen, J. (2025) · PLoS Pathogens · doi:10.1371/journal.ppat.1013344
Self-citationCho, K., Baek, Y., Kwon, H.-J., Jeong, H. J., Choi, B., Park, W.-R., Sharif, M., Nguyen, T. H., Jeong, S.-H., Lee, I., et al. (2025) · Research Square · doi:10.21203/rs.3.rs-6651542/v1
Zhong, C., She, G., Zhao, Y., Liu, Y., Liu, J., Wei, X., Chen, Z., Zhao, K., Zhao, Z., Zhichao, X., et al. (2024) · Figshare · doi:10.6084/m9.figshare.25566274
Zhong, C., She, G., Zhao, Y., Liu, Y., Liu, J., Wei, X., Chen, Z., Zhao, K., Zhao, Z., Zhichao, X., et al. (2024) · Figshare · doi:10.6084/m9.figshare.25566379
Park, J. Y., & Lee, H. (2025) · Life · doi:10.3390/life16010058
COVID-19 challenges and its therapeutics
Liang, L., Li, Y., Lu, S., Wang, J., & Yao, H. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-36518-8.00024-2
Caractérisation des activités antivirales des anticorps anti-VIH-1 et anti-SARS-CoV-2
Dufloo, J. (2021) · theses.fr (ABES) · doi:10.70675/215798eaz7f82z4e57za8eazf4453d37b8c8
Kim, Y. W., Lee, S. J., Lee, W. M., Kim, S.-J., & Ahn, D. (2026) · Journal of Microbiology and Biotechnology · doi:10.4014/jmb.2602.02038 · Cited by 1
Wang, M., Wang, Z., Liu, C., Duan, J., Wu, T., Fu, Q., & Su, X. (2026) · The FASEB Journal · doi:10.1096/fj.202600391r
Zhang, Y., Kang, L., Zhong, Y. D., Shao, S., Xue, S., Liu, C., Zheng, X., Lin, J., Chen, Y., Luo, F., et al. (2026) · MedComm · doi:10.1002/mco2.70821
Epistasis between SARS-CoV-2 M and N Proteins Balances Particle Assembly and Immune EvasionPreprint
Barrera-Vasquez, A., Khalid, M. M., Ramos, H., Rosecrans, J., Marcela Ferrés, G., Angulo, J., Ott, M., & Taha, T. Y. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.06.29.735107
Angamarca-Iguago, J., Parise-Vasco, J. M., Reytor-González, C., Cagua-Ordoñez, J. C., & Simancas‐Racines, D. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27135994
DNA oligonucleotides block viral entry of SARS-CoV-2 Omicron variants
Acuña, J. A., Gabriel, B., Ayyanathan, K., Miller, J., Li, Y., Whig, K., Zhu, Y., McGrath, M. E., Hewins, P., Jurado, K. A., et al. (2026) · PLoS Pathogens · doi:10.1371/journal.ppat.1014461
Metadata
- Authors
- Zheng, Y., Zhuang, M.-W., Han, L., Zhang, J., Nan, M.-L., Zhan, P., Kang, D., Liu, X., Gao, C., & Wang, P.-H.
- Affiliations
- Shandong University (CN)
- Corresponding author
- Gao, Chengjiang
- Wang, Pei-Hui
- ORCID
- Venue
- Signal Transduction and Targeted Therapy
- Published
- 2020-12-28
- Volume
- 5
- Issue
- 1
- Pages
- 299-299
- ISSN
- 2059-3635 (ISSN-L)
- PMC
- PMC7768267
- OpenAlex
- W3115832826
- Cited by
- 302
- References
- 47
- Citations by year
- 2026: 13 · 2025: 23 · 2024: 36 · 2023: 56 · 2022: 93 · 2021: 80 · 2020: 1
- FWCI
- 20.14
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- Signal Transduction and Targeted Therapy (publishedVersion, cc-by)
- bioRxiv (Cold Spring Harbor Laboratory) (acceptedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- eScholarship (California Digital Library) (submittedVersion, cc-by)
- Funders
- Shandong University (2020XGB03)
- National Natural Science Foundation of China (81525012, 81930039, 31730026, 81901604, COVID-19)
- China Postdoctoral Science Foundation (2018M642662)
- Government of Jiangsu Province
- Natural Science Foundation of Jiangsu Province (SBK2020042706)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › interferon and immune responses
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Epidemiology › Virology and Viral Diseases
- Keywords
- SARS-CoV-2, membrane proteins, interferon evasion, type I interferon, interferon lambda, RIG-I, MDA5, MAVS, TBK1, IRF3, vesicular stomatitis virus, poly(I:C), viral replication
- MeSH terms
- DEAD Box Protein 58, Interferon-Induced Helicase, IFIH1, COVID-19, SARS-CoV-2, Coronavirus M Proteins, Interferon Lambda, Animals, Chlorocebus aethiops, HeLa Cells, Humans, Interferon Type I, Interferons, Receptors, Immunologic, Vero Cells, Viral Matrix Proteins, Signal Transduction, HEK293 Cells
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review